Safety and tolerability of combination therapy vs. standard treatment alone for patients with previously treated non-small cell lung cancer


Nivolumab (OPDIVO) is the standard treatment for patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Nivolumab blocks a signal that naturally inhibits the body’s immune system from attacking a tumor. CV301 is a cancer vaccine designed to induce a specific immune response within a tumor. Investigators from CCR and the maker of CV301 want to determine if combining this vaccine with nivolumab can enhance the immune system’s ability to attack tumors. James Gulley, M.D., Ph.D., is leading a team from the Genitourinary Malignancies Branch, the Laboratory of Tumor Immunology and Biology and the Thoracic and Gastrointestinal Oncology Branch to test the safety and tolerability of this combination treatment and to see if it can improve survival for patients with metastatic NSCLC. For more information on this trial: https://clinicaltrials.gov/ct2/show/NCT02840994

Summary Posted: 03/2017